Board of Directors

Elaine Campbell

Board Member
Former President of AstraZeneca Canada with 30+ years in pharmaceutical leadership.

Elaine Campbell is a retired senior executive with over 30 years of experience in the pharmaceutical and chemical industries. She has extensive commercial expertise in sales and marketing, spanning early and pre-launch product development, product launch, and life-cycle management.

Elaine has held leadership positions in both global and North American markets and served as President of AstraZeneca Canada from 2012 to 2015. Her deep knowledge of strategic planning and operational execution has contributed to the success of numerous commercial initiatives across therapeutic areas.

Craig Fraser

Chairman of the Board, SaNOtize
Global biopharma executive with over 30 years’ experience in commercialization, strategy, and leadership.

Craig Fraser has over 34 years of experience leading successful global biopharmaceutical businesses, from startups to multi-billion-dollar operations. He has held executive roles at major pharmaceutical companies and brings deep expertise across nearly all functions of the industry.

Most recently, he served as Chairman and CEO of publicly listed Windtree Therapeutics for eight years and currently sits on the management boards of multiple life sciences companies, including SaNOtize. His leadership spans Oncology, Rare Diseases, Cardiovascular, Immunology, Anti-Infectives, and Hospital/Critical Care segments.

Craig’s broad background includes successful fundraising (including IPOs), corporate strategy, M&A, licensing, and global commercialization. He is also a veteran of both the U.S. Marine Corps and the U.S. Army.

Chris Miller, PhD, BA, RT

Chief Science Officer, SaNOtize Cofounder
A pioneer in nitric oxide technology and therapeutic research.

Dr. Miller has 30 years of experience in nitric oxide (NO) research, drug and device development, and commercialization. He has served as CEO/CSO in nitric oxide biotech startup fundraising and out-licensing, and has expertise in clinical trial design and execution, intellectual property, regulatory affairs, and management.

Among his contributions, which include more than 40 peer-reviewed papers, Dr. Miller characterized one of the antimicrobial mechanisms of action of NO and identified its effective dose against multiple microbes (bacteria, fungi, and viruses). He also helped design two of the first three FDA-approved NO gas delivery devices and led the first human clinical trial demonstrating that inhaled NO is safe in healthy adults as a potential antimicrobial strategy.

Dr. Miller was an assistant professor in the Faculty of Medicine (Respiratory & Infectious Diseases Division) at the University of British Columbia, Canada. He holds a PhD in Experimental Medicine and degrees in Health Management and Respiratory Therapy.

Gilly Regev, PhD

Chief Strategy and Innovation Officer, SaNOtize Cofounder
Experienced biotech executive with hands-on experience in launching pharmaceutical enterprises.

For the past 30 years, Dr. Regev has been a leader in biochemistry and microbiology R&D. She has extensive experience in drug development, intellectual property strategy, clinical trials, and early-stage biotech fundraising and licensing.

Since co-founding SaNOtize in 2017, Dr. Regev has guided the company from early research through product approval and revenue generation in record time. She led a major Series B funding round and secured non-dilutive grants. Before SaNOtize, she served as Chief Scientific Officer at Bovicor (animal health) and Director of R&D at Nitric Solutions, Inc. Dr. Regev earned her PhD in Biochemistry from the Hebrew University of Jerusalem.

In 2022, she was named one of the Top 25 Women Leaders in Biotechnology by the Healthcare Technology Report, and in 2021 won the YWCA Women of Distinction Award for Entrepreneur and Innovator of the Year. Dr. Regev also sits on the Vancouver Chapter of the Weizmann Institute advisory board and the Canadian Antimicrobial Innovation Coalition Steering Committee.

Kerry Liu

Board Member
Venture investor and serial entrepreneur with a background in AI, retail tech, and corporate strategy.

Kerry Liu has served as a Venture Investor at Horizons Ventures since 2022, and currently sits on or observes the boards of Syzygy, Fleet Aerospace, H2Pro, Zero Avia, HzO, and Promise Robotics.

Prior to Horizons, Kerry spent a decade as a technology entrepreneur. He was on the early management team at Strangeloop Networks (acquired by Radware) and later founded Rubikloud—an AI-driven retail/CPG platform acquired by Kinaxis in 2022. Following that acquisition, he oversaw global product management and corporate development at Kinaxis.

Kerry holds a Bachelor of Commerce from the University of British Columbia and is a Chartered Accountant. Based in Toronto, he is also an active angel investor and advisor to numerous startups.

Dan Suesskind

Board Member
Former Global CFO of Teva Pharmaceuticals; led company through major growth and global expansion.

Dan Suesskind served as Global Chief Financial Officer of Teva Pharmaceuticals from 1987 to 2008. Under his leadership, Teva grew from a $28 million operation to an $11 billion pharmaceutical leader with a market capitalization of $45 billion.

Dan spearheaded Teva’s NASDAQ listing, executed numerous strategic acquisitions, and raised over $6 billion in U.S. capital markets. His financial stewardship was pivotal in transforming Teva into a global pharmaceutical powerhouse.

Mary Rotunno

Board Member
Experienced healthcare and life sciences legal advisor with executive leadership and board credentials.

Mary L. Rotunno, J.D., is a legal and strategic advisor to life sciences and healthcare companies. She currently serves on the board of Vistagen, a late-stage clinical biopharma company, and previously chaired the board of Momentum for Health, a leading Silicon Valley mental health services provider.

Over the last decade, she was General Counsel and a member of the Executive Leadership Team at El Camino Health, a $1.4 billion revenue health system. Prior to that, she spent 11 years as Senior Counsel and Client Service Leader at CommonSpirit Health (formerly Dignity Health) in the San Francisco Bay Area.

Earlier in her career, Mary held legal roles at Varian Medical Systems, Manatt, Phelps & Phillips, Golden Living, and Pillsbury Winthrop Shaw Pittman. She holds NACD Directorship Certification and is a graduate of Stanford Directors’ College.